Evidence map›Paper›PMID 41862942›Full record

ArticleOrphanet journal of rare diseases2026

Bridging the gap between patient and physician perspectives on management of generalized myasthenia gravis: a Delphi consensus study.

Andrew Chan, Monika Kaempf, Wolfgang N Löscher, John Vissing, Johan Voerman, Eva Frostell-Pyhäjärvi, Sari Atula

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Andrew ChanDepartment of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. andrew.chan@insel.ch.
Monika KaempfASRIMM, Association for Neuromuscular Diseases covering Swiss French Cantons, Yverdon-les-Bains, Switzerland.
Wolfgang N LöscherDepartment of Neurology, Medical University Innsbruck, Innsbruck, Austria.
John VissingCopenhagen Neuromuscular Center, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Johan VoermanDiagnosis Working Group, Spierziekten Netherlands, Delft, Netherlands.
Eva Frostell-PyhäjärviFinnish MG Association, Ex-European Myasthenia Gravis Association, Vantaa, Finland.
Sari AtulaHUS Neurocenter, University of Helsinki, Helsinki, Finland.

Funding

Alexion, Rare Disease Company of AstraZeneca Alexion, Rare Disease Company of AstraZeneca
6 · The paper itself

Abstract

backgroundThere is currently limited data to guide treatment selection, dosing, combination strategies and sequencing in the management of myasthenia gravis (MG). Additionally, MG symptoms are heterogenous between people and with time, requiring an individualized treatment approach. As such, successful patient-physician communication is key. This Delphi project was undertaken by MG specialists and patient representatives to explore their opinion on improving MG management via effective physician-patient communication and collaboration approach.

methodsThis mixed-methods study was conducted in two phases. In Phase I, seven MG specialists and two patient representatives contributed to idea generation. Relevant insights informed the development of the Phase II Delphi survey. A panel of 16 MG specialists and seven patient representatives participated in a two-round Delphi survey. Consensus was defined as ≥ 70% agreement or disagreement on a 6-point Likert scale. Participants responded to the survey from what they considered an ideal scenario, regardless of their real-world experience.

resultsConsensus was achieved on 89% of all statements. Key areas of alignment were – importance of incorporating patient preferences on quality of life (QoL), sustained symptom control, route of administration, and side effects profile. Both groups agreed that current clinical practices insufficiently integrate mental health considerations and patient engagement remains suboptimal. Two key areas of misalignment were – patient representative and physicians had different perspective on how well physicians understood patient preferences and both groups showed different interpretations of side effects (adverse reaction versus issues of tolerability).

conclusionThis Delphi consensus found that while physician and patient representatives shared similar perspectives these were not always reflected in current clinical practice due to differences in understanding of patient preferences. Prioritizing structured conversations on QoL, treatment expectations, and side effect were found important for physicians while improving access to information, openly communicating and actively participating in treatment decisions were key outcomes for patients. This study lays a valuable foundation for deepening conversations and alignment on key topics in MG management among the medical, patient and caregiving communities.

Indexed as

Myasthenia GravisAdultDelphi TechniqueFemaleHumansMalePhysician-Patient RelationsPhysiciansQuality of LifeSurveys and QuestionnairesDelphi consensusEuropeGeneralized myasthenia gravisQuality of life

Identifiers

PMID41862942
PMCPMC13126803

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.